Nuvation Bio Inc. (NYSE: NUVB) reported updated data from its Phase 2 J201 study of safusidenib in patients with chemotherapy- ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE